Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B4
Welty FK, Schulte F, Alfaddagh A, Elajami TK, Bistrian BR, Hardt M
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 49 citations
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- National Heart, Lung, and Blood Institute
- Government
- National Center for Advancing Translational Sciences
- Government
- NCATS NIH HHS
- Government
- NHLBI NIH HHS
- Grants
- National Center for Advancing Translational Sciences (UL1TR001102); National Heart, Lung, and Blood Institute (P50-HL083813)
Based on 4 listed funder(s).
Publication
- Published
- 2021-03-22 · FASEB J · vol. 35 · issue 4 · p. e21448
- Publisher
- Wiley
- Cited
- 54 citations · more than 96% of similar papers · 4.7× the field average
- Impact
- Top 10% most cited in its field
- References
- 44 works
- Access
- Open access (repository copy)
- Research areas
- Fatty Acid Research and Health · Eicosanoids and Hypertension Pharmacology · Cholesterol and Lipid Metabolism
- Keywords
- Eicosapentaenoic acid, Internal medicine, Docosahexaenoic acid, Medicine, Cardiology, Chemistry, Fatty acid, Biochemistry, Polyunsaturated fatty acid
- MeSH
- humans, docosahexaenoic acids, eicosapentaenoic acid, leukotriene b4, prostaglandins, hydroxymethylglutaryl-coa reductase inhibitors, aged, middle aged, female, male, plaque, atherosclerotic
6 authors
From US
- Francine K. Welty · correspondingBeth Israel Deaconess Medical Center
- Fabian SchulteHarvard University; The Forsyth Institute
- Abdulhamied AlfaddaghBeth Israel Deaconess Medical Center
- Tarec K. ElajamiBeth Israel Deaconess Medical Center
- Bruce Ryan BistrianBeth Israel Deaconess Medical Center
- Markus HardtHarvard University; The Forsyth Institute
Abstract
Inflammation in arterial walls leads to coronary artery disease (CAD). We previously reported that a high omega-3 fatty index was associated with prevention of progression of coronary atherosclerosis, a disease of chronic inflammation in the arterial wall. However, the mechanism of such benefit is unclear. The two main omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors of specialized pro-resolving lipid mediators (SPMs)-resolvins and maresins-which actively resolve chronic inflammation. To explore whether SPMs are associated with coronary plaque progression, levels of SPMs and proinflammatory mediators (leukotriene B4 [LTB4 ] and prostaglandins) were measured using liquid chromatography-tandem mass spectrometry in 31 statin-treated patients with stable CAD randomized to either EPA and DHA, 3.36 g daily, or no EPA/DHA (control). Coronary plaque volume was measured by coronary computed tomographic angiography at baseline and at 30-month follow-up. Higher plasma levels of EPA+DHA were associated with significantly increased levels of two SPMs-resolvin E1 and maresin 1-and 18-hydroxy-eicosapentaenoic acid (HEPE), the precursor of resolvin E1. Those with low plasma EPA+DHA levels had a low (18-HEPE+resolvin E1)/LTB4 ratio and significant plaque progression. Those with high plasma EPA+DHA levels had either low (18-HEPE+resolvin E1)/LTB4 ratios with significant plaque progression or high (18-HEPE+resolvin E1)/LTB4 ratios with significant plaque regression. These findings suggest that an imbalance between pro-resolving and proinflammatory lipid mediators is associated with plaque progression and potentially mediates the beneficial effects of EPA and DHA in CAD patients.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.